about
Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary studyTipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary studyOld drug tipepidine as new hope for children with ADHDAn Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.Treatment of puberty trichotillomania with low-dose aripiprazole.Increased Serum Levels of Oxytocin in 'Treatment Resistant Depression in Adolescents (TRDIA)' Group.Treatment of refractory catatonic schizophrenia with low dose aripiprazole.Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study.Ifenprodil for the treatment of flashbacks in adolescent female posttraumatic stress disorder patients with a history of abuse.Old drug ifenprodil, new hope for PTSD with a history of childhood abuse.Increased serum levels of serine enantiomers in patients with depression.Does hypofrontality expand to global brain area in progression of schizophrenia?: a cross-sectional study between first-episode and chronic schizophrenia.Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity Disorder.A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.Japanese adaptation of the Bad Sobernheim Stress Questionnaire-Brace for patients with adolescent idiopathic scoliosisPediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription databaseStudy of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double-blind, placebo-controlled trialGenetic combination risk for schizophrenia
P50
Q28240200-3F18AC41-EE11-499A-9CB7-D02507660E95Q28307232-81DEA46C-5B87-46A2-B926-807E05B58999Q29012639-A0BC56BB-AA89-4E10-BEAB-36BE63809A12Q35579197-9E8194A2-772B-4E4D-8EA1-3C482C37EDABQ35755244-C8A00A71-8069-4DF0-B3F2-F3569841F235Q36106577-D086CE8E-0381-4C33-A031-EAA52ABCEF09Q36323380-D457B6D9-2C76-4153-A3BA-5DDDB6193737Q39170484-A770C7D2-7F4B-4F5D-A2AC-B60F79DC1250Q43131864-04DEBC75-64E2-4022-BDF5-DCEA651B0C9FQ46486352-382DFFB3-8567-485B-A754-BAF8D866EB17Q47634591-5AE0EEBA-FFE5-482C-9A4D-829F2BE7511DQ48071667-B00C4F31-0D16-4B48-9310-8BE54E1F98CCQ48790127-C362D330-599B-47BA-8254-5BA53806DEC8Q50309732-D39152F2-401E-4ABA-A665-638424762D12Q50652601-47BE58A1-A575-43CE-9571-6D2FFEA0CA9FQ90082597-70E534EC-57D2-438B-B315-00B2F5F5C300Q90101991-2243F823-DDE7-46B9-9AFF-3FF0FF595B50Q91526855-5AED060C-729E-4525-982E-570C5CE8B721Q93061770-7B80438B-531C-4DFD-BD43-70DB82677C82
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tsuyoshi Sasaki
@ast
Tsuyoshi Sasaki
@en
Tsuyoshi Sasaki
@es
Tsuyoshi Sasaki
@nl
type
label
Tsuyoshi Sasaki
@ast
Tsuyoshi Sasaki
@en
Tsuyoshi Sasaki
@es
Tsuyoshi Sasaki
@nl
prefLabel
Tsuyoshi Sasaki
@ast
Tsuyoshi Sasaki
@en
Tsuyoshi Sasaki
@es
Tsuyoshi Sasaki
@nl
P106
P108
P31
P496
0000-0001-8502-6469